Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.5.0.2
Revenue (Details)
$ in Thousands, £ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2014
GBP (£)
Jun. 30, 2014
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Milestone
Jun. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2016
USD ($)
Milestone
item
Sep. 30, 2015
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2015
USD ($)
Collaboration and License Agreement                            
Revenue recognized       $ 2,416   $ 4,948   $ 5,662 $ 10,459          
Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd                            
Collaboration and License Agreement                            
Number of additional target peptides, that the entity has right to nominate | item               3            
Upfront payment received £ 25 $ 42,100                        
Milestone payments received             $ 14,400             $ 7,200
Number of milestones achieved during the period | Milestone       0       0            
Royalties received               $ 0            
Written notice period required to be served for the termination of agreement for material breach (in days)               60 days            
Notice period required to be served for the termination of agreement or specific program (in days)               60 days            
Maximum combination studies permitted | item               8            
Revenue recognized       $ 2,416   $ 4,948   $ 5,662 $ 10,459          
Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd | Change in service delivery period in collaboration and license agreement                            
Collaboration and License Agreement                            
Revenue recognized       $ (336)                    
Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd | Change in service delivery period in collaboration and license agreement | Adjustment                            
Collaboration and License Agreement                            
Revenue recognized         $ (2,785)                  
Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd | Change in service delivery period in collaboration and license agreement | Forecast adjustment                            
Collaboration and License Agreement                            
Revenue recognized     $ (336)             $ 1,642 $ 1,187 $ 1,793 $ (1,344)